filgotinib
Trade name: Jyseleca
Small moleculeexperimental
Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV. — Wikipedia
Clinical trial activity
52 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
34
Phase 3
16
Phase 4
6
Earliest trial started Aug 1, 2010 (NCT01179581)
Timeline
Indications
Approved for
Studied for
- Arthritis, Juvenile · Phase 1
- Arthritis, Psoriatic · Phase 3
- Arthritis, Rheumatoid · Phase 4
- Axial Spondyloarthritis · Phase 3
- Behcet Syndrome · Phase 2
- Biological Availability · Phase 1
- Biomarkers · Phase 3
- Colitis, Ulcerative · Phase 4
- Crohn Disease · Phase 3
- Healthy Volunteers · Phase 1
- Immunoglobulin G4-Related Disease · Phase 2
- Inflammatory Bowel Diseases · Phase 2
- Interleukin-6 · Phase 3
- Janus Kinase Inhibitors · Phase 3
- Kidney Diseases · Phase 2
- Kidney Failure, Chronic · Phase 1
- Lupus Erythematosus, Cutaneous · Phase 2
- Myositis · Phase 2
- Spondylitis, Ankylosing · Phase 3
- Ultrasonography · Phase 3
- Uveitis · Phase 2
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
Tyrosine-protein kinase JAK2 inhibitor
JAK1 preferential inhibitory activity
- Tyrosine-protein kinase JAK3INHIBITOR
Tyrosine-protein kinase JAK3 inhibitor
JAK1 preferential inhibitory activity
- Tyrosine-protein kinase TYK2INHIBITOR
Tyrosine-protein kinase TYK2 inhibitor
JAK1 preferential inhibitory activity
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1- Mol. weight
- 425.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFilgotinib ↗
- ChEMBLCHEMBL4298167 ↗
- ChEMBLCHEMBL3301607 ↗
Also known as
- filgotinib
- filgotinib
- filgotinib
- filgotinib
- g-146034
- g-146034
- glpg0634
- glpg0634
- glpg0634
- glpg-0634
- glpg-0634
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06964113 | Phase 4 | Jun 11, 2025 | Eisai, Gilead Sciences |
| NCT06865417 | Phase 3 | May 31, 2025 | Alfasigma S.p.A. |
| NCT06687551 | Phase 4 | Jan 1, 2025 | University of Toulouse |
| NCT06625242 | Phase 4 | Oct 15, 2024 | Eisai |
| NCT06527534 | Phase 4 | Jul 15, 2024 | University of Verona |
| NCT06222034 | Phase 1 | May 13, 2024 | Alfasigma S.p.A. |
| NCT06285539 | Phase 2 | Mar 12, 2024 | Alfasigma S.p.A., Utrecht University |
| NCT06043739 | Phase 1 | Sep 22, 2023 | Galapagos NV |
| NCT05785611 | Phase 3 | Apr 5, 2023 | Galapagos NV |
| NCT05502731 | Phase 4 | Oct 31, 2022 | Galapagos NV, Leiden University |
| NCT05479058 | Phase 3 | Jul 26, 2022 | Galapagos NV |
| NCT04985435 | Phase 4 | May 12, 2021 | Galapagos NV, Leiden University, Medical Center Leeuwarden, Rheumatology Research Center Northern Netherlands |
| NCT05090410 | Phase 3 | Mar 3, 2021 | Gilead Sciences, University of Nagasaki |
| NCT04483687 | Phase 3 | Dec 31, 2020 | Galapagos NV, Gilead Sciences |
| NCT04483700 | Phase 3 | Dec 31, 2020 | Galapagos NV, Gilead Sciences |
| NCT04608344 | Phase 1 | Nov 4, 2020 | Galapagos NV, Gilead Sciences |
| NCT04115839 | Phase 3 | Nov 30, 2019 | Galapagos NV, Gilead Sciences |
| NCT04115748 | Phase 3 | Nov 30, 2019 | Galapagos NV, Gilead Sciences |
| NCT03926195 | Phase 2 | May 28, 2019 | Galapagos NV, Gilead Sciences |
| NCT03417778 | Phase 1 | Apr 3, 2018 | Galapagos NV, Gilead Sciences |
Showing 20 of 52 trials
Page 1 / 3
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 41 | 20 | 4 | 2010 |
| Gilead Sciences | For profit | 25 | 22 | 4 | 2014 |
| Alfasigma S.p.A. | For profit | 3 | 2 | 3 | 2024 |
| SGS Life Sciences | For profit | 3 | 0 | 1 | 2010 |
| Eisai | For profit | 2 | 2 | 1 | 2024 |
| Leiden University | Academic/Hospital | 2 | 1 | 1 | 2021 |
| Medical Center Leeuwarden | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Rheumatology Research Center Northern Netherlands | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Nagasaki | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Verona | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Utrecht University | Academic/Hospital | 1 | 1 | 1 | 2024 |
12 organizations
Page 1 / 1